$10.11
10.25% yesterday
NYSE, Nov 21, 10:00 pm CET
ISIN
US29384C1080
Symbol
TRDA

Entrada Therapeutics Stock price

$10.11
+3.75 58.96% 1M
+2.42 31.47% 6M
-7.18 41.53% YTD
-7.94 43.99% 1Y
-4.31 29.89% 3Y
-13.84 57.79% 5Y
-13.84 57.79% 10Y
-13.84 57.79% 20Y
NYSE, Closing price Fri, Nov 21 2025
+0.94 10.25%
ISIN
US29384C1080
Symbol
TRDA
Industry

Key metrics

Basic
Market capitalization
$386.4m
Enterprise Value
$59.6m
Net debt
positive
Cash
$326.8m
Shares outstanding
38.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.3 | 9.7
EV/Sales
1.0 | 1.5
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
81.5%
Return on Equity
15.3%
ROCE
-31.3%
ROIC
-146.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$61.5m | $40.0m
EBITDA
$-117.4m | $-149.9m
EBIT
$-121.6m | $-161.2m
Net Income
$-103.5m | $-137.6m
Free Cash Flow
$-130.3m
Growth (TTM | estimate)
Revenue
-71.4% | -81.0%
EBITDA
-293.9% | -395.2%
EBIT
-313.2% | -443.0%
Net Income
-288.3% | -309.7%
Free Cash Flow
-645.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-190.8% | -374.5%
EBIT
-197.6%
Net
-168.2% | -343.8%
Free Cash Flow
-211.7%
More
EPS
$-2.5
FCF per Share
$-3.4
Short interest
4.3%
Employees
183
Rev per Employee
$1.2m
Show more

Is Entrada Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Entrada Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Entrada Therapeutics forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Entrada Therapeutics forecast:

Buy
90%
Hold
10%

Financial data from Entrada Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
62 62
71% 71%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
11% 11%
67%
- Research and Development Expense 142 142
18% 18%
230%
-117 -117
294% 294%
-191%
- Depreciation and Amortization 4.20 4.20
19% 19%
7%
EBIT (Operating Income) EBIT -122 -122
313% 313%
-198%
Net Profit -103 -103
288% 288%
-168%

In millions USD.

Don't miss a Thing! We will send you all news about Entrada Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Entrada Therapeutics Stock News

Positive
Seeking Alpha
5 days ago
Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration income. TRDA is heavily investing in its Duchenne muscular dystrophy pipeline, with multiple early-stage clinical programs converging on key data readouts in 2026. Despite widening losses, TRDA maintains a strong cash position of $326.8 million, sufficient to fund operati...
Neutral
GlobeNewsWire
16 days ago
-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 -- -- Filed for regulatory authorization in U.K. to initiate ELEVATE-50-201, a global Phase 1/2 MAD clinical study of ENTR-601-50 -- -- Expected cash runway extended into Q3 2027 wi...
Neutral
GlobeNewsWire
25 days ago
BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare Conference in London Dipal Doshi, Chief Executive Officer, will deliver a company presentation on Tuesday, November 18, 2025, at 5:00 p.m.
More Entrada Therapeutics News

Company Profile

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Head office United States
CEO Dipal Doshi
Employees 183
Founded 2016
Website www.entradatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today